Press Releases

Press Releases

April 13, 2022
HOOKIPA to Participate in the Kempen Life Sciences Conference
NEW YORK and VIENNA, Austria, April 13, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the company will participate in investor meetings at the Kempen
February 9, 2022
HOOKIPA to Present at the SVB Leerink Global Healthcare Conference
NEW YORK and VIENNA, Austria, Feb. 09, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the company will participate in the virtual 11th Annual SVB
January 18, 2022
HOOKIPA Announces First Patient Enrolled in Phase 2 Trial Evaluating HB-200 and Pembrolizumab for Treatment of Head and Neck Cancer and Reports FDA’s Fast Track Designation
First patient dosed with HB-200 and pembrolizumab combination for treatment of 1 st -line advanced/metastatic head and neck cancer in Phase 2 arm of ongoing Phase 1/2 trial Fast Track Designation granted for HB-200 in combination with pembrolizumab for treatment of 1 st -line head and neck cancer